Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Benefit of immune checkpoint inhibitors (ICI) for patients with advanced esophageal squamous cell carcinoma and low PD-L1 expression: A systematic review and meta-analysis.
Authors
Mario Machado Lopes
A.C. Camargo Cancer Center, São Paulo, Brazil
Mario Machado Lopes , Viviane Alencar , Isadora Martins de Sousa , Ana Carolina Marin Comini , Marcos Pedro Guedes Camandaroba
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 346)
DOI
10.1200/JCO.2024.42.3_suppl.346
Abstract #
346
Poster Bd #
G7
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Updated pooled analyses of first-line anti-PD1/PD-L1 inhibitors plus chemotherapy in advanced esophageal squamous cell carcinoma.
First Author: Maysa Vilbert
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial.
First Author: Xiaoting Ma
Poster
2020 ASCO Virtual Scientific Program
Outcomes in patients with advanced non-small cell lung cancer (aNSCLC) and high PD-L1 expression treated with immune checkpoint inhibitor monotherapy: An FDA-pooled analysis.
First Author: Sujay Yogesh Shah
Poster
2024 ASCO Annual Meeting
PD-L1 expression in pulmonary sarcomatoid carcinoma and response to immunotherapy.
First Author: Lingzhi Hong